Clinical trial · Interventional
Chemical Peels and Fractional Laser on IGF-1 Levels in Skin
Impact of Chemical Peels and Fractional Laser on IGF-1 Levels in Skin
NCT03775031CI-TRIAL-00047814unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the impact of fractional laser versus chemical peels on IGF-1 levels in skin.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Skin Cancer | Malignant Skin Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fractional Laser and Chemical Peel | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- ACTIVE_COMPARATOR
- label
- Fraxel 1927nm
- description
- Treatment setting for Fraxel 1927 nm: 20 mJ, Treatment level 8, 6 passes
- interventionNames
- Device: Fractional Laser and Chemical Peel
- type
- ACTIVE_COMPARATOR
- label
- Fraxel 1550nm
- description
- Treatment setting for Fraxel 1550 nm: 70 mJ, Treatment level 6, 6 passes
- interventionNames
- Device: Fractional Laser and Chemical Peel
- type
- ACTIVE_COMPARATOR
- label
- 25% TCA Peel
- description
- 25% TCA on 5 x 5 cm of sun exposed back
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: * Male and female subjects \>55 years old * Fitzpatrick type I-II * Able to provide informed consent. * Cutaneous photodamage of 3 or above on the Larnier photodamage scale (see Appendix). Exclusion Criteria: * Prior laser or peel treatment in the area evaluated in the current study in the past year. * Currently taking immunosuppressant medications known to interfere wound healing or anti-inflammatory medications (such as NSAIDs, or steroids). * Subjects who have underlying diseases that could alter wound healing response (such as Diabetes). * Currently taking insulin. * History of substance abuse, mental dysfunction, or other factors limiting ability to cooperate with study. * History of abnormal scarring such as Keloids. * History of vitiligo. * Allergy or sensitivity or allergy to topical anesthesia * Inability to use sunscreen. * History of smoking in the last 10 years * Scar or prior surgery in the area of treatment. * Use of isotretinoin in the prior 6 months * Subjects who have bleeding disorders or who are taking anticoagulants
References
Publications (0)
Data not yet available
No reference posted for this study.